252 related articles for article (PubMed ID: 21291356)
1. Therapies for neurological disease in the mucopolysaccharidoses.
Anson DS; McIntyre C; Byers S
Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
[TBL] [Abstract][Full Text] [Related]
2. Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.
Holley RJ; Wood SR; Bigger BW
ACS Chem Neurosci; 2019 Jan; 10(1):18-20. PubMed ID: 30136572
[TBL] [Abstract][Full Text] [Related]
3. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
[TBL] [Abstract][Full Text] [Related]
4. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.
Fecarotta S; Gasperini S; Parenti G
Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204
[TBL] [Abstract][Full Text] [Related]
5. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis.
Safary A; Akbarzadeh Khiavi M; Omidi Y; Rafi MA
Cell Mol Life Sci; 2019 Sep; 76(17):3363-3381. PubMed ID: 31101939
[TBL] [Abstract][Full Text] [Related]
6. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
Pan D
Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
[TBL] [Abstract][Full Text] [Related]
7. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS.
Giugliani R; Vairo F; Kubaski F; Poswar F; Riegel M; Baldo G; Saute JA
Lancet Child Adolesc Health; 2018 Jan; 2(1):56-68. PubMed ID: 30169196
[TBL] [Abstract][Full Text] [Related]
8. Current and potential therapeutic strategies for mucopolysaccharidoses.
Noh H; Lee JI
J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
Lau AA; Hemsley KM
J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
12. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases.
Gurda BL; Vite CH
Hum Mol Genet; 2019 Oct; 28(R1):R119-R131. PubMed ID: 31384936
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology applied to treatment of mucopolysaccharidoses.
Schuh RS; Baldo G; Teixeira HF
Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
[TBL] [Abstract][Full Text] [Related]
14. [Treatment prospects of lysosomal storage disorders].
Reismann P; Tulassay Z
Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for the treatment of mucopolysaccharidoses.
Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
[TBL] [Abstract][Full Text] [Related]
16. New prospects for the treatment of lysosomal storage diseases.
Schiffmann R; Brady RO
Drugs; 2002; 62(5):733-42. PubMed ID: 11929328
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
Valayannopoulos V
Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
[TBL] [Abstract][Full Text] [Related]
18. Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses.
Fachel FNS; Frâncio L; Poletto É; Schuh RS; Teixeira HF; Giugliani R; Baldo G; Matte U
Adv Drug Deliv Rev; 2022 Dec; 191():114616. PubMed ID: 36356930
[TBL] [Abstract][Full Text] [Related]
19. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
Critchley BJ; Gaspar HB; Benedetti S
Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for lysosomal storage disorders.
Beck M
Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
